Core Insights - Helix BioPharma Corp. presented new data on its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference, highlighting its commitment to developing innovative cancer therapies [1][2] Group 1: Presentation Highlights - The presentation titled "Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies" was delivered by Dr. Jonathan Davis, showcasing Helix's leadership in ADC technology [2] - CEACAM6 was identified as a promising therapeutic target due to its high expression in various epithelial cancers, association with poor clinical outcomes, and limited presence in healthy tissues [3] - Data presented demonstrated the tumor-selective binding profile of Helix's proprietary anti-CEACAM6 VHH, supporting the development of next-generation ADCs that minimize off-target effects while delivering potent therapeutic payloads [3][4] Group 2: Company Pipeline and Innovations - Helix's lead candidate, Tumor Defense Breaker™ L-DOS47, is designed to enhance the sensitivity of CEACAM6-expressing tumors to therapy and has shown favorable safety and clinical activity in Phase I/II studies for non-small cell lung cancer (NSCLC) [6] - The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability comparable to intravenous administration [6]

Core Viewpoint - Helix BioPharma Corp. has extended its Research and Exclusive Option Agreement with metaShape Pharma AG for the compound LEUMUNA™ until December 31, 2028, allowing further research and development in metabolic diseases while maintaining a focus on oncology assets [1][4]. Group 1: Agreement Details - The original agreement was established in April 2023 between metaShape and Laevoroc Immunology AG, granting metaShape an exclusive research license and an option for a commercial license for LEUMUNA™ [2]. - The extension of the agreement provides additional time to advance research activities and supports the progression of the program toward clinical-stage development [4]. Group 2: Compound Development - MS 001, the compound under development, is designed as an orally administered co-therapy to GLP-1 receptor agonists, aimed at enhancing adipose tissue reduction and weight loss durability [2]. - Preclinical studies indicated that MS 001 increased levels of inosine and NAD+, which improved mitochondrial function and energy expenditure in adipose tissue, leading to better weight loss outcomes in mice [3]. Group 3: Company Perspectives - The CEO of metaShape expressed excitement about the progress of MS 001 and the developments in the program [5]. - Helix's CEO highlighted the quality of preclinical data around MS 001, particularly its effects on NAD+ biology and fat metabolism, indicating potential benefits across various disease settings [5]. Group 4: Company Backgrounds - MetaShape Pharma, founded in 2023, focuses on developing first-in-class metabolic therapies to address metabolic dysfunction [6]. - Helix BioPharma specializes in oncology, with a pipeline that includes Tumor Defense Breaker™ L-DOS47 and two pre-IND candidates: LEUMUNA™ and GEMCEDA™, aimed at treating hard-to-treat cancers [7].

Core Insights - Helix BioPharma Corp. has filed its unaudited interim financial statements for the three-month period ending October 31, 2025, along with management's discussion and analysis and certifications from the CEO and CFO [1] Company Overview - Helix BioPharma is focused on developing innovative solutions for difficult-to-treat cancers, with a pipeline led by Tumor Defense Breaker™ L-DOS47, an antibody-enzyme conjugate aimed at enhancing therapy sensitivity in CEACAM6-expressing tumors [2] - L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its targeting foundation with the company's next-generation bi-specific antibody-drug conjugates currently in discovery [2] - The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug designed to expand treatment options for advanced cancers [2]

Toronto, Ontario--(Newsfile Corp. - December 1, 2025) - The following is a list of Upcoming Meeting Dates for Reporting Issuers in Canada. The data is supplied by Issuing Companies through the service of CDS Clearing and Depository Services Inc.Company NameRecord DateMeeting DateType ANGKOR RESOURCES CORP December 19, 2025January 29, 2025AS  Aether Global Innovations CorpDecember 18, 2025February 5, 2025A  Agility Capital Holding Inc. December 15, 2025January 23, 2025AGS AnalytixInsight Inc. December 22, 2 ...

Core Viewpoint - Helix BioPharma Corp. is not aware of any undisclosed material information that could explain the recent increase in its share price and trading volume [1] Company Overview - Helix BioPharma is a clinical-stage oncology company focused on developing solutions for hard-to-treat cancers [2] - The company's leading product is Tumor Defense Breaker™ L-DOS47, an antibody-enzyme conjugate aimed at enhancing the effectiveness of therapies for CEACAM6-expressing tumors [2] - L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its foundation with the company's next-generation bi-specific antibody-drug conjugates currently in discovery [2] - Helix is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a first-in-class oral gemcitabine prodrug designed for advanced cancers [2] Stock Information - Helix BioPharma is listed on multiple exchanges: TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0) [3]

Core Insights - Helix BioPharma Corp. announced the publication of a peer-reviewed article on the safety of L-DOS47, an unconventional antibody-drug conjugate, in treating advanced non-small cell lung cancer (NSCLC) [1][2] Company Overview - Helix BioPharma is a clinical-stage oncology company focused on developing innovative treatments for hard-to-treat cancers, with L-DOS47 as its lead candidate [4] - The company is also advancing two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, a first-in-class oral gemcitabine prodrug [5] Clinical Study Findings - The Phase I/II study of L-DOS47 demonstrated good tolerability at doses up to 13.55 µg/kg, with a median progression-free survival (PFS) of 4.1 months in the highest dosing quartile [3] - No complete or partial responses were observed, but higher doses correlated with a statistically significant extension in PFS (P=0.0203) [3] - CEACAM6 was found to be highly expressed in nearly half of NSCLC cases, suggesting its potential as a biomarker for patient selection in future trials [3] Future Development Plans - Helix plans to advance L-DOS47 into a new clinical study in combination with the PD-1 inhibitor pembrolizumab, aiming to enhance the efficacy of immunotherapies by neutralizing tumor acidity [3] - The company has received positive feedback from the FDA regarding the planned Phase I/II study in combination with pembrolizumab [3]

Core Insights - Helix BioPharma Corp. has appointed Veronika Kandziora as Chief Operating Officer and Dr. Jessica Kourniaktis as Director of Communications, aiming to strengthen its leadership team during a pivotal stage of development [1][4][5] Leadership Appointments - Veronika Kandziora brings over 20 years of experience in biopharma, financial, and consulting sectors, with a strong background in corporate strategy and stakeholder engagement [2] - Dr. Jessica Kourniaktis has 10 years of experience in life sciences communications, having founded a consultancy and served in leadership roles in biopharma startups [3] Company Vision and Strategy - The company is focused on developing novel therapies for hard-to-treat cancers, with a diverse pipeline of drug candidates [6] - The lead candidate, Tumour Defence Breaker™ L-DOS47, is designed to neutralize the microenvironment of solid tumors and has completed Phase Ib studies in non-small cell lung cancer [6] Operational Goals - Kandziora emphasizes the need for structure, clarity, and strategic alignment to empower the team and innovate effectively [4] - Kourniaktis aims to enhance the company's communication strategy to better articulate its vision and engage stakeholders [5]

Core Viewpoint - Helix BioPharma Corp. held its Annual General and Special Meeting on March 26, 2025, where shareholders voted overwhelmingly in favor of all proposed resolutions, indicating strong support for the company's strategic direction and governance [1][2]. Voting Results - A total of 40,294,667 common shares were voted, representing 76.00% of the total issued and outstanding shares [1]. - All four director nominees were re-elected with votes in favor ranging from 99.99% to 99.99% [2]. - The appointment of Clearhouse LLP as the auditor was approved with 99.61% of votes in favor [2]. - The asset transactions with Laevoroc Immunology AG and Laevoroc Chemotherapy AG were approved with 99.61% of votes in favor [3]. - The equity draw-down subscription facility providing access to CA$25,000,000 was approved with 99.61% of votes in favor [4]. - The amendment for share consolidation on a ratio of up to five pre-consolidation shares for one post-consolidation share was approved with 99.98% of votes in favor [5]. - The resolution to change the company's name to "Aconara Pharma Corp." was approved with 99.60% of votes in favor [6]. - The approval of unallocated options and the Equity Compensation Plan for a further three years was approved with 99.60% of votes in favor [7]. Company Overview - Helix BioPharma is focused on developing novel therapies for hard-to-treat cancers, with a pipeline that includes the lead candidate Tumour Defence Breaker™ L-DOS47, which targets CEACAM6-expressing solid tumors [10].

Core Viewpoint - Helix BioPharma Corp. is extending its Annual General and Special Meeting to March 26, 2025, to secure shareholder approval for proposed asset acquisitions and financing arrangements [1][2]. Group 1: Meeting Details - The Annual General and Special Meeting has been rescheduled to March 26, 2025, to allow more time for shareholder approval regarding asset acquisitions from Laevoroc Immunology AG and Laevoroc Chemotherapy AG [1]. - The Ontario Superior Court of Justice approved the application to hold the Meeting by the new date on February 26, 2025 [2]. - Meeting materials, including the Notice of Meeting and Voting Instruction Form, were mailed to shareholders and posted on SEDAR+ on February 24, 2025 [3]. Group 2: Shareholder Participation - Shareholders of record as of January 31, 2025, are eligible to vote at the Meeting and are encouraged to vote in advance [4]. - Proxies must be received by 10 a.m. (EST) on March 24, 2025, to be counted [4]. Group 3: Company Overview - Helix BioPharma Corp. is focused on developing novel therapies for hard-to-treat cancers, with a pipeline that includes a proprietary technology platform targeting CEACAM6-expressing solid tumors [6]. - The lead candidate, Tumour Defence BreakerTM L-DOS47, is an antibody-enzyme conjugate that aims to enhance anti-cancer immunity and has completed Phase Ib studies in non-small cell lung cancer [6][7].